Description

Irinotecan for Infusions 20 mg/ml. 25 ml. /500 mg. Vial

Ingredients

Active ingredient: Irinotecan hydrochloride trihydrate. Inactive ingredients may include polysorbate 80, lactic acid, and water for injections.

Dosage

Dosage: The recommended dosage of Irinotecan for infusion is determined by the patient’s body surface area and health condition. It is administered intravenously over a specific period as directed by a healthcare professional.

Indications

Indications: Irinotecan is indicated for the treatment of colorectal cancer that has spread to other parts of the body. It is often used in combination with other chemotherapy medications.

Contraindications

Contraindications: Irinotecan is contraindicated in patients with a known hypersensitivity to the drug or its components. It should not be used in patients with severe bone marrow suppression.

Directions

Administration: Irinotecan should only be administered by healthcare professionals experienced in the use of chemotherapy agents. It is given as an intravenous infusion and the infusion rate should be carefully controlled.

Scientific Evidence

Irinotecan exerts its antitumor effects by inhibiting topoisomerase I, an enzyme involved in DNA replication. This action leads to DNA damage and cell death in rapidly dividing cancer cells. Clinical trials have shown the efficacy of Irinotecan in improving survival rates and reducing tumor size in patients with advanced colorectal cancer.

Additional Information

It is important to monitor patients receiving Irinotecan for potential side effects such as diarrhea, neutropenia, and nausea. Close medical supervision is necessary to manage and mitigate these adverse reactions. Patients should also be informed about the possible long-term effects of Irinotecan treatment on their overall health and well-being.

In conclusion, Irinotecan for infusions 20 mg/ml. 25 ml. /500 mg. vial is a crucial chemotherapy medication in the treatment of advanced colorectal cancer. Its pharmacological action, supported by scientific evidence from clinical trials, demonstrates its effectiveness in combating cancer cells. Healthcare providers play a vital role in ensuring safe administration and monitoring of Irinotecan therapy to optimize patient outcomes.